La Roche and Spark announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.
Roche and Spark both filed a Premerger Notification and Report Form under the HSR Act on March 1, 2019 with respect to the pending acquisition. On March 18, 2019, Roche withdrew the March 1, 2019 filing and refiled a Premerger Notification and Report Form.
The Swiss company said it was extending its offer to May 2 from the original deadline of Wednesday, having received support from holders of only 29.4 percent of Spark shares. It needs a majority for its offer to go through.
“All terms and conditions of the offer shall remain unchanged during the extended period,” Roche said in a statement on the $114.50 per share offer it announced in February.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
